Sorafenib Related compound H Tosylate |
|
|---|---|
| CAT. No : | S490047 |
| CAS. No : | NA |
| Mol. F : | C21H16ClF3N4O3.C7H8O3S |
| Mol. Wt : | 637.03 g/mol |
| Synonyms : | 4-(4-{3-[2-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N-methylpicolinamide Tosylate |
| Chemical Name : | 4-(4-(3-(2-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide 4-methylbenzenesulfonate |
| Stock Status : | Instock |
- Buy High-Quality Sorafenib Related compound H Tosylate from Simson Pharma Limited at best competitive price.
- Every compound produced by Simson Pharma is accompanied by Certificate of Analysis.
Product Applications & Regulatory Search Terms:
Sorafenib Related compound H Tosylate for Method Validation | Sorafenib Related compound H Tosylate Reference Standard | Sorafenib Related compound H Tosylate for ANDA Filing | Sorafenib Related compound H Tosylate for Forced Degradation Studies | Sorafenib Related compound H Tosylate Identification Standards | Sorafenib Related compound H Tosylate for DMF Filing | Buy high quality Sorafenib Related compound H Tosylate | Purchase Sorafenib Related compound H Tosylate | Sorafenib Related compound H Tosylate suppliers | Sorafenib Related compound H Tosylate manufacturers | Sorafenib Related compound H Tosylate price | Sorafenib Related compound H Tosylate exporter | Order Sorafenib Related compound H Tosylate | Enquire Sorafenib Related compound H Tosylate | Sorafenib Related compound H Tosylate cost | Sorafenib Related compound H Tosylate Supplier | Sorafenib Related compound H Tosylate Distributor
Disclaimer:
The information provided on this webpage is based on the best available knowledge at the time of creation. However, accuracy and completeness are not guaranteed. Product specifications may change without notice, and it is the responsibility of the purchaser, user, or importer of record to verify the accuracy and suitability of the product at the time of ordering.
This product is intended for research use only and is not approved for human consumption.
